1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-22.96%
Cash & equivalents declining -22.96% while Drug Manufacturers - Specialty & Generic shows -9.97% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-22.96%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -8.62%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
10.86%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.17%. Jim Chanos might see a serious red flag in ballooning receivables.
-1.92%
Inventory growth less than half of Drug Manufacturers - Specialty & Generic median of 3.35%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
No Data
No Data available this quarter, please select a different quarter.
-4.41%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -2.87%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-4.46%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.25%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-0.84%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-6.42%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.40%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-2.86%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of -0.99%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
638.51%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
-97.61%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-0.00%
Below half the Drug Manufacturers - Specialty & Generic median of -1.11%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
0.5-0.75x Drug Manufacturers - Specialty & Generic median of -0.99%. Guy Spier is cautious about potential underinvestment relative to sector.
7.42%
Payables growth 1.1-1.25x Drug Manufacturers - Specialty & Generic median of 6.04%. John Neff wonders if the company is pushing out payments more than peers.
-11.69%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-5.02%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
92.78%
Below half Drug Manufacturers - Specialty & Generic median of -0.70%. Jim Chanos sees a potential sales pipeline shortfall.
-12.14%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
31.30%
Below half Drug Manufacturers - Specialty & Generic median of -2.26%. Joel Greenblatt sees more conservative short-term leverage than peers.
-7.01%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-9.96%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
15.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-7.34%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -2.17%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.60%
Below half Drug Manufacturers - Specialty & Generic median of -1.46%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.34%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-66.43%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-3.13%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-0.65%
0.75-0.9x Drug Manufacturers - Specialty & Generic median of -0.82%. John Neff wonders if expansions lag peers.
638.51%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-6.92%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.10%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
10.49%
Near Drug Manufacturers - Specialty & Generic median 10.80%. Charlie Munger sees typical yoy changes in net debt among the sector.
